Clinical trials
Prostate Cancer (Diagnosis) clinical trials
Below are recruiting prostate cancer (diagnosis) clinical trials, each written for real people, not researchers. We’re tracking 431 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06138067Recruiting
Navigator program to help cancer patients join clinical trials
This study tests if a patient navigator can help more people with prostate or kidney cancer enroll in clinical trials. You may be assigned to work with a navigator who helps find a trial that fits your needs.
Baltimore, MarylandAges 18 years+ - NCT07517198RecruitingPhase 1
EXS74539 Study for Advanced Solid Tumors
This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT07181473RecruitingPhase 1
Safety of TJ101 for advanced solid tumors
This trial tests a new drug called TJ101 for people with advanced solid tumors who have tried standard treatments or have no standard options. It aims to see if the drug is safe and how well it works.
Orlando, FloridaAges 18 years+ - NCT05497024Recruiting
Decision aid testing for older men on prostate cancer surveillance
This trial tests an English decision aid (a patient guide) to help older men understand and feel comfortable with “active surveillance” for localized prostate cancer. It also checks how easy to use it is for patients, caregivers, and prostate cancer clinicians.
Houston, TexasAges 65 years+ - NCT05665738Recruiting
Two high-dose radiation treatments for early prostate cancer
This trial tests a shorter course of high-dose radiation therapy for prostate cancer that hasn't spread. It aims to make treatment more convenient while keeping it effective.
San Francisco, CaliforniaAges 18 years+ - NCT07608848RecruitingEarly Phase 1
Imaging study of new cancer-targeting radioactive drugs
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
Perth, Western AustraliaAges 18 years+ - NCT02381990Recruiting
MRI- and ultrasound-guided freezing treatment for low-risk prostate cancer
This trial tests using MRI and ultrasound together to guide freezing (cryoablation) treatment for prostate cancer. It may help target the tumor more precisely while avoiding areas that could cause side effects.
Miami Lakes, FloridaAges 55 years+ - NCT06990880RecruitingPhase 1/Phase 2
A study of a new drug for advanced prostate cancer
This study tests an experimental drug, alone or with other treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if it can shrink tumors or slow the disease.
Phoenix, ArizonaAges 18 years+ - NCT05116475RecruitingPhase 3
New prostate cancer trial adding darolutamide to standard treatment
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
Chambray-lès-ToursAges 18–120 - NCT07672119Recruiting
Heart risks in older men on enzalutamide or darolutamide
This study looks at heart-related risks in older men with advanced prostate cancer who are taking enzalutamide or darolutamide. It may help doctors better understand how to manage heart health during treatment.
Whippany, New JerseyAges 55 years+ - NCT06696326Recruiting
New PET scan for prostate cancer detection
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Xiamen, FujianAges 18–90 - NCT07451795RecruitingPhase 2
SHR-1701 with targeted radiation for advanced prostate cancer
This trial tests a new drug called SHR-1701 combined with a precise type of radiation (SBRT) for men with prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if this combination can help control the cancer.
FujianAges 18–80 - NCT07300566Recruiting
Focal versus whole-gland radiation boost for localized prostate cancer
This trial compares two ways of giving a radiation boost (brachytherapy) to the prostate for men with localized prostate cancer. One method targets only the visible tumor, while the other treats the whole gland, and the study aims to see if the focal approach works as well with fewer side effects.
London, OntarioAges 18 years+ - NCT07244341RecruitingPhase 1
Valemetostat and darolutamide for advanced prostate cancer
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
La Jolla, CaliforniaAges 18 years+ - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT06130995RecruitingPhase 1
Relugolix and enzalutamide for high-risk prostate cancer
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
Oklahoma City, OklahomaAges 18 years+ - NCT04895839Recruiting
Mental health coaching for men with prostate cancer
This study looks at what affects mental health while men with prostate cancer take part in a patient empowerment program. It may help you and others by testing a practical support approach delivered through email, texts, and online videos.
Ghent, East FlandersAges 18 years+ - NCT06363266Recruiting
Tempo program for men with prostate cancer and their caregivers
This study tests a program called TEMPO to help men with prostate cancer and their caregivers manage anxiety. You and your chosen caregiver will use an online tool designed to support your well-being.
Montreal, CanadaAges 18 years+ - NCT07406282Recruiting
Darolutamide for new prostate cancer that spread
This study looks at how well darolutamide and similar drugs work for men whose prostate cancer has just spread to other parts of the body. It aims to understand real-world outcomes in urology clinics.
Cleveland, OhioAges 18 years+ - NCT07436078Recruiting
Genetic testing study for African American cancer survivors
This study offers genetic testing and counseling to African American cancer survivors. It aims to see if a culturally tailored approach helps more people understand their cancer risk and get the testing they need.
Detroit, MichiganAges 20–79 - NCT05936736Recruiting
One-time radiation for prostate cancer with bladder-sparing approach
This trial tests whether giving prostate radiation in one treatment session can work well while protecting the bladder. It may help certain people with localized prostate cancer by aiming for good cancer control with fewer bladder/urinary side effects.
Milan, MIAges 18 years+ - NCT05104515RecruitingPhase 1
First cancer vaccine test for advanced lung, ovarian, or prostate cancer
This Phase 1 study tests OVM-200, a new cancer vaccine, to see how it is tolerated and how it affects the immune system in people with advanced NSCLC, ovarian cancer, or prostate cancer. You may be eligible if your cancer has already had approved treatment(s) and no further standard options are planned within the first two months.
London, LondonAges 18–75 - NCT05209243Recruiting
Treating limited-spread prostate cancer with radiation plus hormone therapy
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
MadridAges Any age - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
Dothan, AlabamaAges 18 years+
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (diagnosis)?
- Yes. Clin2 currently lists 431 recruiting prostate cancer (diagnosis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (diagnosis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (diagnosis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.